Xiaofeng A Su
Overview
Explore the profile of Xiaofeng A Su including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morel K, German B, Hamid A, Nanda J, Linder S, Bergman A, et al.
J Clin Invest
. 2024 Nov;
135(2.
PMID: 39560993
Phenotypic plasticity is a hallmark of cancer and is increasingly realized as a mechanism of resistance to androgen receptor-targeted (AR-targeted) therapy. Now that many prostate cancer (PCa) patients are treated...
2.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
Oncogene
. 2024 Sep;
43(43):3197-3213.
PMID: 39266679
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
3.
Su X, Stopsack K, Schmidt D, Ma D, Li Z, Scheet P, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(36):e2405543121.
PMID: 39190349
Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this...
4.
Do B, Hsu P, Vermeulen S, Wang Z, Hirz T, Abbott K, et al.
Dev Cell
. 2024 Jun;
59(16):2203-2221.e15.
PMID: 38823395
Control of cellular identity requires coordination of developmental programs with environmental factors such as nutrient availability, suggesting that perturbing metabolism can alter cell state. Here, we find that nucleotide depletion...
5.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
bioRxiv
. 2024 May;
PMID: 38766099
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
6.
Wang Y, Gao B, Zhang L, Wang X, Zhu X, Yang H, et al.
Nat Commun
. 2024 May;
15(1):3819.
PMID: 38714829
No abstract available.
7.
Wang Y, Gao B, Zhang L, Wang X, Zhu X, Yang H, et al.
Nat Commun
. 2024 Feb;
15(1):1568.
PMID: 38383600
Drugs targeting the DNA damage response (DDR) are widely used in cancer therapy, but resistance to these drugs remains a major clinical challenge. Here, we show that SYCP2, a meiotic...
8.
Brown R, Su X, Fair S, Wu K, Verra L, Jong R, et al.
PLoS Biol
. 2022 Dec;
20(12):e3001940.
PMID: 36574440
Expansion of structure-forming CAG/CTG repetitive sequences is the cause of several neurodegenerative disorders and deletion of repeats is a potential therapeutic strategy. Transcription-associated mechanisms are known to cause CAG repeat...
9.
Stopsack K, Su X, Vaselkiv J, Graff R, Ebot E, Pettersson A, et al.
Mol Cancer Res
. 2022 Sep;
21(1):14-23.
PMID: 36125519
Implications: Considering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely...
10.
Trakala M, Aggarwal M, Sniffen C, Zasadil L, Carroll A, Ma D, et al.
Genes Dev
. 2021 Jul;
35(15-16):1079-1092.
PMID: 34266888
Chromosome gains and losses are a frequent feature of human cancers. However, how these aberrations can outweigh the detrimental effects of aneuploidy remains unclear. An initial comparison of existing chromosomal...